Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy

Epilepsy Research

Volumn 42, Issue 1, 2000, Pages 23-31

  Gidal, Barry E ^a   Anderson, Gail D ^b   Rutecki, Paul R ^c   Shaw, Ronald ^d   Lanning, Angela ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d Central Wisconsin Center   (United States)

Author keywords

Drug interaction; Lamotrigine; NONMEM; Pharmacokinetics; Valproic acid

Indexed keywords

CARBAMAZEPINE; DRUG METABOLIZING ENZYME; ENZYME INDUCING AGENT; ENZYME INHIBITOR; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; AGE; ARTICLE; BODY WEIGHT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG METABOLISM; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYPHARMACY; POPULATION RESEARCH; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; ALGORITHMS; ANTICONVULSANTS; CHILD; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEVELOPMENTAL DISABILITIES; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMAN; MALE; MIDDLE AGE; MODELS, BIOLOGICAL; POPULATION; SUPPORT, NON-U.S. GOV'T; TRIAZINES; VALPROIC ACID;

EID: 0033834187     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(00)00160-1     Document Type: Article

References (35)

1. Bartoli A., Guerrini R., Belmonte A. et al. The influence of dosage, age and comedication on lamotrigine steady state concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther. Drug Monit. 19:1997;252-260.
2. Battino, D., Croci, D., Granata, T., et al., 1997. Lamotrigine plasma concentrations in children and adults: influence of age and associated therapy. Ther Drug Monit., 19.
3. Beal, S.L., Boeckman, A.J., and Sheiner, L.B. (1988-1992). NONMEM User's Guide. University of California at San Francisco, San Francisco.
4. Bhaumik S., Branford D., Duggirala C. et al. A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. Seizure. 6:1997;127-133.
5. Brodie M.J., Yuen A.W.C., Group S. Lamotrigine substitution study: evidence for synergism with sodium valproate. Epilepsy Res. 26:1997;423-432.
6. Chen C., Casale E.J., Duncan B. et al. Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs. Pharmacotherapy. 19:1999;437-441.
7. Cohen A.F., Land G.S., Breimer D.D. et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin. Pharmacol. Ther. 42:1987;535-541.
8. Coppola G., Pascotto A. Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial. Brain Dev. 19:1997;398-402.
9. Dulac O., Kaminski A. Use of lamotrigine in Lennox-Gastaut and related epilepsy syndromes. J. Child Neurol. 12(suppl 1):1997;S23-S28.
10. Faught, E., Morris, G., Jacobson, M., et al., 1999. Adding lamotrigine to valproate: incidence of rash and other adverse effects. Epilepsia, 40.
11. Ferrie C.D., Panayiotopoulos C.P. Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy. Seizure. 3:1994;157-159.
12. Green M.D., Bishop W.P., Tephley T.R. Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab. Disp. 23:1995;299-302.
13. Guberman A.H., Besag F.M., Brodie M.J. et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia. 40:1999;985-991.
14. Hussein Z., Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br. J. Clin. Pharmacol. 43:1997;457-465.
15. Jawad S., Yuen W.C., Peck A.W. et al. Lamotrigine: single dose pharmacokinetics and inital 1 week experience in refractory epilepsy. Epilepsy Res. 1:1987;194-201.
16. King J.A., Knight J.E., Oommen K.J. Efficacy of Lamotrigine in the developmentally disabled. Epilepsia. 37:1996;162.
17. Kriel R.L., Fischer J.H., Cloyd J.C. et al. Valproic acid pharmacokinetics in children: III. Very high dosage requirements. Pediatr. Neurol. 2:1986;202-208.
18. Lensmeyer G., Gidal B., Weibe D. Optimized high-performance liquid chromatography method for lamotrigine in serum with concomitant determination of phenytoin, carbamazepine and carbamazepine epoxide. Ther. Drug Monit. 19:1996;292-300.
19. Mandema J.W., Verotta D., Sheiner L.B. Building population pharmacokinetic-pharmacodynamic models: models for covariate effects. J. Pharmacokinet. Biopharm. 20:1992;511-528.
20. Mattson R.H. The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps. Epilepsia. 37:1996;S45-S53.
21. May T.W., Rambeck B., Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther. Drug Monit. 18:1996;523-531.
22. McKee J.R., Sunder T.R., Vuona A. et al. Effects of Lamictal® adjunctive therapy in mentally retarded patients with epilepsy: an interim analysis. Epilepsia. 39:1998;130.
23. Motte J., Trevatham E., Arvidsson J. et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. New Engl. J. Med. 337:1997;1807-1812.
24. Nanry K.P., Barrett P.S. Serum concentration during conversion from VPA to Lamictal (LTG) monotherapy: an interim analysis. Epilepsia. 40(7):1999;95.
25. Pellock J.M., Hunt P.A. A decade of modern epilepsy therapy in institutionalized mentally retarded patients. Epilepsy Res. 25:1996;263-268.
26. Pisani F., Oteri G., Russo M.F. et al. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia. 40:1999;1141-1146.
27. Posner J., Holdich T., Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healty volunteers. J. Pharm. Med. 1:1991;121-128.
28. Sheiner L.B., Rosenberg B., Marathe V.V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J. Pharmacokinet. Biopharm. 5:1977;445-479.
29. Sorensen T., Mai J., Friis M.L. et al. Long-term follow-up on lamotrigine in treatment of epilepsy in the mentally retarded. Epilepsia. 39:1998;130.
30. Steffenburg U., Hedstrom A., Lindroth A. et al. Intractable epilepsy in a population-based series of mentally retarded children. Epilepsia. 39:1998;767-775.
31. Sunder T.R. Meeting the challenge of epilepsy in persons with multiple handicaps. J. Child Neurol. 12(1):1997;S38-S43.
32. Uvebrant P., Bauziene R. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics. 25:1994;284-289.
33. Vauzelle-Kervroedam F., Rey E., Cieuta C. et al. Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. Br. J. Clin. Pharmacol. 41:1996;325-330.
34. Whiting B., Kelman A.W., Grevel J. Population pharmacokinetics, theory and clinical application. Clin. Pharmacokinet. 11:1986;387-401.
35. Yuen A.W., Land G., Weatherley B.C. et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br. J. Clin. Phrmacol. 33:1992;511-513.